Portage Biotech Inc (PRTG) NPV
Portage Biotech Inc. is a Canada-based clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers and virus-like particles. Within these five platforms, the Company has 10 products, which is under development with multiple clinical readouts. The Company’s subsidiaries include SalvaRx Limited, iOx Therapeutics Ltd., Saugatuck Therapeutics, Ltd. and Portage Developmental Services.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.